NEWS HIGHLIGHTSMedia Articles Related to Lupron (Leuprolide)
Among Patients Carrying BRCA Mutations, PARP Inhibitor Shows Activity In Pancreatic, Prostate Cancers
Source: Health News from Medical News Today [2013.05.18]
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June (Abstract #11024)...
Advanced Prostate Cancer Drug Xofigo Approved By FDA
Source: Health News from Medical News Today [2013.05.17]
Xofigo (radium Ra 223 dichloride) has been approved by the US FDA for symptomatic late-stage (metastatic) castration-resistant prostate cancer that has reached bones but not other organs, i.e. with no known visceral metastatic disease. The Food and Drug Administration (FDA) approved Xifogo under the priority review program, three months ahead of schedule. According to an online FDA communiqué published this week, Xofigo is aimed at male patients whose prostate cancer metastasized despite receiving medical or surgical interventions to reduce testosterone levels...
Xofigo Approved for Prostate Cancer
Source: MedicineNet Prostate Cancer Specialty [2013.05.17]
Title: Xofigo Approved for Prostate Cancer
Category: Health News
Created: 5/16/2013 4:36:00 PM
Last Editorial Review: 5/17/2013 12:00:00 AM
Androgen Deprivation Therapy For Prostate Cancer Can Cause Osteoporosis
Source: Bones / Orthopedics News From Medical News Today [2013.05.16]
Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment...
FDA Approves New Drug to Fight Advanced Prostate Cancer
Source: MedicineNet Prostate Cancer Specialty [2013.05.16]
Title: FDA Approves New Drug to Fight Advanced Prostate Cancer
Category: Health News
Created: 5/15/2013 12:36:00 PM
Last Editorial Review: 5/16/2013 12:00:00 AM
Published Studies Related to Lupron (Leuprolide)
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. [2011.09]
PURPOSE: We investigated the efficacy and safety of degarelix treatment and the effects of switching from leuprolide to degarelix in an ongoing extension study with a median 27.5-month followup of a pivotal 1-year prostate cancer trial... CONCLUSIONS: Data support the statistically significant prostate specific antigen progression-free survival benefit for degarelix over leuprolide seen during year 1 and the use of degarelix as first line androgen deprivation therapy as an alternative to a gonadotropin-releasing hormone agonist. Copyright (c) 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. [2011.06.30]
We performed a randomized trial to compare IVF outcomes in 54 poor responder patients undergoing a microdose leuprolide acetate (LA) protocol or a GnRH antagonist protocol incorporating a luteal phase E(2) patch and GnRH antagonist in the preceding menstrual cycle.
Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. [2011.06]
The aim of the study was to compare the onset, incidence and frequency/intensity of hot flushes during androgen-deprivation therapy with a gonadotropin-releasing hormone antagonist (GnRH) blocker versus an agonist using data from a randomized Phase 3 clinical trial...
Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. [2011.04]
OBJECTIVE: To compare the efficacy of leuprolide and continuous oral contraceptives in the treatment of endometriosis-associated pain...
Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. [2010.11]
OBJECTIVE: To determine whether insulin sensitizers lower androgen levels and whether androgen suppression improves insulin resistance in nondiabetic postmenopausal women... They confirm that treatment of insulin resistance decreases T production in this population and demonstrate that pharmacologic lowering of T does not affect insulin resistance.
Clinical Trials Related to Lupron (Leuprolide)
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases [Recruiting]
The purpose of this study it to determine whether the use of a gonadotropin releasing
hormone (GnRH)-agonist (depot-leuprolide acetate) during cyclophosphamide (CYC) therapy in
women with rheumatic diseases will provide greater ovarian protection than placebo.
Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation [Recruiting]
Background:
- One way to treat certain cancers of the blood and immune system is to give a patient
stem cells from the bone marrow of a donor whose genes are very similar but not
identical to the patient's. One problem with these transplants is that the new immune
cells may not work as well in the recipient as they did in the donor. The result may be
that the immune system will not work as well. This can increase the risk of severe
infections and other complications.
- Researchers are studying the use of drugs that lower hormone levels and may allow the
immune system to recover in a way that improves white blood cell function. In this
study they will be looking at the drug lupron, a drug that lowers estrogen or
testosterone levels, to see if it might improve the function of the newly transplanted
cells.
Objectives:
- To determine whether lupron improves immune system function after bone marrow
transplantation from a donor with similarities in their immune cells (matched to each
other).
- To evaluate the effectiveness of a nuclear medicine test with a radiotracer drug FLT in
imaging studies. FLT will be used to image the immune system function in patients who
have received bone marrow from the donor.
Eligibility:
- People between 15 (or as young as 9 in those who have gone through puberty) and 40
years of age. These patients must have acute myelogenous leukemia, acute lymphocytic
leukemia, or high-risk myelodysplastic syndrome. They must also be eligible for a bone
marrow transplant.
- Genetically similar donors for the patients who are eligible for a transplant.
Design:
- People taking part in the study will be screened with a physical examination, medical
history, blood and urine tests, and imaging studies. Patients who are not in remission
or who require a bone marrow donor search may receive chemotherapy first.
- Donors will provide bone marrow for transplant according to standard bone marrow
transplant (BMT) procedures.
- All women and half of the men will receive regular lupron doses 2 weeks before BMT to
suppress hormone function.
- All recipients will receive 4 days of radiation followed by 2-4 days of chemotherapy
before the bone marrow transplant (depending on age). Recipients will also receive
other drugs to prevent transplant rejection and other complications of transplantation.
- Recipients will be monitored in the hospital for 4 weeks after transplant with blood
tests and other studies.
- Some recipients will have an imaging study with FLT during the protocol. These imaging
studies will take place before the transplant, on days 5 and 28 after transplant, and
at a later time to be determined by the study researchers.
- Following discharge, participants will be monitored closely for up to 6 months, with
regular but less frequent followup visits for at least 5 years. Study-related
medications, including vaccinations for the new immune system, will be provided by the
National Institutes of Health during the hospital stay and after discharge.
Pharmacodynamics of Lorelin Depot (Leuprorelin Acetate - Bergamo) Compared to Lupron Depot � (Leuprorelin Acetate - Abbot) [Recruiting]
The primary objective of this study is to examine, in healthy subjects, the comparative
pharmacodynamics of Lorelin Depot (leuprorelin), manufactured by the Chemical
Pharmaceutical Laboratory Bergamo Ltda with the product Lupron Depot ® (leuprorelin),
manufactured by Abbott Laboratories Ltd, through the strength of biological markers follicle
stimulating hormone (FSH), luteinizing hormone (LH) and total testosterone, associated with
the activity of the substance.
Secondarily be observed safety (tolerability) of subjects in clinical research through the
comparison of clinical and laboratory parameters pre-and post-study, and incidence of
adverse events.
Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation [Recruiting]
The purpose of this study is to help determine if palifermin and/or leuprolide acetate can
help the immune system recover faster following a stem cell transplant. Blood stem cells are
very young blood cells that grow in the body to become red or white blood cells or
platelets. The transplant uses stem cells in the blood from another person. The donor can be
a family member or a volunteer donor. This is called an allogeneic stem cell transplant.
The investigators want to see if palifermin and/or leuprolide acetate can help the immune
system recover faster after an allogenic transplant because experiments have shown they may
be able to do this.
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) [Recruiting]
There is no effective standard treatment for fibrolamellar liver cancer that cannot be
removed by surgery. The investigators want to find out what effects, good and/or bad, 3
drugs called letrozole, leuprolide and everolimus will have on cancer. All of these drugs
are FDA approved for the treatment of different cancers. Letrozole and leuprolide stop the
body from producing estrogen, a normal hormone produced by the body. Too much estrogen may
help fibrolamellar liver cancer grow. Everolimus is a drug that may block other chemicals in
the body that can help cancer grow. The combination of letrozole and leuprolide plus
everolimus may work well together.
Reports of Suspected Lupron (Leuprolide) Side Effects
Headache (21),
Fatigue (14),
Hot Flush (12),
Pain (9),
Night Sweats (8),
Abortion Spontaneous (8),
Back Pain (8),
Dyspnoea (8),
Arthralgia (8),
Bone Pain (7), more >>
|
